Closely watched AstraZeneca cancer drug fails in mesothelioma

A closely watched AstraZeneca drug did not extend lives of patients with the rare cancer mesothelioma when given on its own, but the drugmaker said it still believed the medicine had a role to play in combination treatments. Mesothelioma is a deadly form of cancer that affects the lining of the lungs or abdomen. In a clinical trial tremelimumab failed to meet the goal of improving overall survival in hard-to-treat mesothelioma patients whose disease had already been treated unsuccessfully with standard drugs, AstraZeneca said on Monday.
Go to Source